IPO
Filter News
Found 17,237 articles
-
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 01, 2021
6/1/2021
Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that it has granted non-statutory stock options to purchase an aggregate of 6,000 ordinary shares of Nabriva Therapeutics as an inducement to two newly-hired employees.
-
Sutro Biopharma Earns Milestone Payment from Bispecific Antibody-Drug Conjugate Collaboration with Merck KGaA, Darmstadt, Germany
6/1/2021
Sutro Biopharma, Inc. announced that it has received a milestone payment under its collaboration and license agreement with the healthcare division of Merck KGaA, Darmstadt, Germany, related to a patient enrollment achievement in the Phase 1 dose escalation and expansion study of M1231 in adult patients with metastatic solid tumors, including non-small cell lung cancer and esophageal squamous cell carcinoma.
-
LifeStance Health Group, Inc. Announces Launch of Initial Public Offering
6/1/2021
LifeStance Health Group, Inc., one of the nation's largest providers of outpatient mental health care, announced it has launched the roadshow for the initial public offering of 40,000,000 shares of its common stock, with 32,800,000 shares being offered by the Company and 7,200,000 shares being offered by selling stockholders pursuant to a registration statement filed on Form S-1 with the Securities and Exchange Commission.
-
Quotient Limited Provides Fourth Quarter and Full Year Fiscal 2021 Results and provides Business Update
6/1/2021
Quotient Limited, a commercial-stage diagnostics company, headquartered in Eysins, Switzerland, reported its fourth quarter fiscal 2021 key achievements and summarized recent business developments.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 01, 2021
6/1/2021
ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that on May 28, 2021 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 89,800 shares of its common stock to four employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan.
-
Centhaquine Improved Shock Index, ARDS, MODS, Reduced Blood Lactate Levels, And 8.8% Absolute Reduction In 28-Day All-Cause Mortality
6/1/2021
Pharmazz, Inc., a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care.
-
Jaguar Health & Dragon SPAC Announce Initial Funding of US$10.8 Million into Dragon SPAC
6/1/2021
Equita Group S.p.A., a leading Italian based investment bank, advising Dragon SPAC; Cantor Fitzgerald & Co. advising Jaguar on non-deal related activities
-
Abbott Issues Updated 2021 Outlook
6/1/2021
Abbott announced an update to its financial outlook for the full-year 2021. The updated guidance is due to significantly lower recent and projected COVID-19 diagnostic testing demand.
-
Shineco, Inc. Announces It’s Unaware of Reason for Stock Volatility
6/1/2021
Shineco, Inc., a producer and distributor of Chinese herbal medicines, organic agricultural and hemp products, announced in response to unusual market activity, and after speaking with its officers, directors, major shareholders and other relevant persons, that it is unaware of the reason behind recent stock price volatility.
-
Quipt Home Medical Reports Record Second Quarter Fiscal 2021 Financial Results
6/1/2021
Quipt Home Medical Corp., a U.S. based leader in the home medical equipment industry, focused on end-to-end respiratory care, announced its second quarter fiscal 2021 financial results and operational highlights.
-
Manufacturing PMI® at 61.2%; May 2021 Manufacturing ISM® Report On Business®
6/1/2021
New Orders, Production & Employment Growing; Supplier Deliveries Slowing at Faster Rate; Backlog Growing; Raw Materials Inventories Growing; Customers' Inventories Too Low; Prices Increasing; Exports and Imports Growing
-
Standard Bariatrics Secures $35M in Series B Funding to Accelerate Development and Commercialization of Their First Bariatric Surgical Platform for Sleeve Gastrectomy
6/1/2021
Cincinnati-based Standard Bariatrics, Inc., has developed the Titan SGS™, a first-of-its-kind design that offers surgeons performing sleeve gastrectomy, the top bariatric surgical procedure for obesity disease, the industry's longest continuous staple cutline of 23 centimeters.
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 01, 2021
6/1/2021
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 24,600 shares of Karyopharm's common stock to six newly-hired employees, with a grant date of May 28, 2021.
-
Scopus BioPharma Announces New Date for 2021 Annual Meeting of Stockholders
6/1/2021
Scopus BioPharma Inc. announced that the board of directors has rescheduled the company’s 2021 Annual Meeting of Stockholders, which will be held on October 8, 2021.
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 01, 2021
6/1/2021
Cytokinetics, Incorporated announced that on May 31, 2021 it granted stock options to purchase an aggregate of 49,500 shares of common stock to eight new employees whose employment commenced in May 2021 as a material inducement to their employment.
-
Kineta Closes $10 Million Financing Round to Advance Anti-VISTA Immuno-oncology Program
6/1/2021
Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, announced the close of its $10 million financing round.
-
Mesa Labs Reports Fourth Quarter and Full Fiscal Year 2021 Results
6/1/2021
Mesa Laboratories, Inc. announced results for the fourth quarter and full year ended March 31, 2021.
-
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - June 01, 2021
6/1/2021
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, announced that on May 28, 2021, the Company granted stock options to six new employees of the Company.
-
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - June 01, 2021
6/1/2021
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that it has granted an inducement award to one new employee, Christopher Markey, who joined the company as Director, Program and Alliance Management.
-
RhoVac Confirms Forecast - BRaVac Phase IIb study recruitment to close in Quarter 3 2021
5/31/2021
RhoVac AB, a Swedish cancer immunotherapy company, announces , May 31, 2021, that it confirms its previous forecast to be able to conclude recruitment for its multi-centre BRaVac Phase IIb study in Quarter 3 2021.